Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
Joint Authors
Brunetti, Antonio
Foti, Daniela
Biagio, Arcidiacono
Mirabelli, Maria
Caroleo, Patrizia
Vero, Raffaella
Brunetti, Francesco Saverio
Corigliano, Domenica Maria
Puccio, Luigi
Chiefari, Eusebio
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-04
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM).
Herein, we aimed to assess the long-term effectiveness and safety of SGLT-2 inhibitors in a Southern Italy population of subjects affected by T2DM.
Patients and Methods.
408 diabetic patients treated with one of the three SGLT-2 inhibitors currently available in Italy (dapagliflozin, empagliflozin, and canagliflozin), either alone or in combination with other antidiabetic drugs, were retrospectively assessed at baseline, during, and after 18 months of continuous therapy.
Results.
Treatment with SGLT-2 inhibitors resulted in a median decrease in HbA1c of 0.9%, with a percentage of decrement of 12 in relation to the baseline value, followed by a significant reduction (P<0.001) in fasting plasma glucose.
Variations in HbA1c occurred independently of the baseline clinical or biochemical characteristics.
In addition, treatment with SGLT-2 inhibitors reduced body weight (P<0.008) and decreased diastolic blood pressure (P=0.004).
With regard to safety outcomes, 66 patients out of 91 stopped SGLT-2 inhibitors during follow-up because of chronic or recurring genital infections, while the rest experienced other adverse events, such as urinary tract infections, polyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control status, and rapid deterioration of renal function.
Conclusion.
In our patients’ population, the glycometabolic effects of SGLT-2 inhibitors were durable and comparable to those observed in multicenter randomized controlled trials.
This notwithstanding safety concerns must be raised regarding the frequent occurrence of genitourinary infections and the risk of a rapid decline of renal function in patients with evidence of volume depletion and/or receiving other medications which can adversely affect kidney function.
American Psychological Association (APA)
Mirabelli, Maria& Chiefari, Eusebio& Caroleo, Patrizia& Vero, Raffaella& Brunetti, Francesco Saverio& Corigliano, Domenica Maria…[et al.]. 2019. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1172902
Modern Language Association (MLA)
Mirabelli, Maria…[et al.]. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1172902
American Medical Association (AMA)
Mirabelli, Maria& Chiefari, Eusebio& Caroleo, Patrizia& Vero, Raffaella& Brunetti, Francesco Saverio& Corigliano, Domenica Maria…[et al.]. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1172902
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1172902